NCT06249308 Liquid Biopsy-based Early Detection of Ovarian Cancer: a Proof-of-concept Study ( PROFOUND-OC )
| NCT ID | NCT06249308 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fudan University |
| Condition | Ovarian Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 168 participants |
| Start Date | 2023-12-18 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 168 participants in total. It began in 2023-12-18 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a multi-center, observational study aiming at developing a machine learning-based early detection model using prospectively collected liquid biopsy samples from newly diagnosed ovarian cancer.
Eligibility Criteria
Inclusion Criteria: * 40-75 years old * Clinically and/or pathologically diagnosed ovarian cancer * No prior or undergoing any systemic or local antitumor therapy, including but not limited to surgical resection, radiochemotherapy, endocrinotherapy, targeted therapy, immunotherapy, interventional therapy, etc. * Able to provide a written informed consent and willing to comply with all part of the protocol procedures Exclusion Criteria: * Pregnancy or lactating women * Known prior or current diagnosis of other types of malignancies comorbidities * Severe acute infection (e.g. severe or critical COVID-19, sepsis, etc.) or febrile illness (body temperature of ≥ 38.0 °C) within 14 days prior to blood draw * Recipients of organ transplant or prior bone marrow transplant or stem cell transplant * Recipients of blood transfusion within 30 days prior to study blood draw * Recipients of therapy in past 14 days prior to blood draw, including oral or IV antibiotics, glucocorticoid, azacitidine, decitabine, procainamine, hydrazine, arsenic trioxide * Other conditions that the investigators considered are not suitable for the enrollment
Contact & Investigator
Hao Wen, M.D., Ph.D.
PRINCIPAL INVESTIGATOR
Fudan University
Frequently Asked Questions
Who can join the NCT06249308 clinical trial?
This trial is open to female participants only, aged 40 Years or older, up to 75 Years, studying Ovarian Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06249308 currently recruiting?
Yes, NCT06249308 is actively recruiting participants. Contact the research team at wenhao_fdc@163.com for enrollment information.
Where is the NCT06249308 trial being conducted?
This trial is being conducted at Guangzhou, China, Shenyang, China, Shanghai, China.
Who is sponsoring the NCT06249308 clinical trial?
NCT06249308 is sponsored by Fudan University. The principal investigator is Hao Wen, M.D., Ph.D. at Fudan University. The trial plans to enroll 168 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.